Current challenges in the development of vaccines for pneumonic plague

Expert Review of Vaccines

Volumn 7, Issue 2, 2008, Pages 209-221

  Smiley, Stephen T ^a  

^a TRUDEAU INSTITUTE   (United States)

Author keywords

Cellular immunity; Humoral immunity; Pneumonic plague; Yersinia pestis

Indexed keywords

BACTERIAL VACCINE; F1 LCRV FUSION PROTEIN; F1 PROTEIN; HYBRID PROTEIN; LCRV PROTEIN; PNEUMONIC PLAGUE VACCINE; PROTEIN; UNCLASSIFIED DRUG;

BACTERIAL VIRULENCE; BIOLOGICAL WARFARE; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FEVER; HEADACHE; HUMAN; LYMPHADENOPATHY; MALAISE; NONHUMAN; PNEUMONIA; PNEUMONIC PLAGUE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SKIN INDURATION; WEAPON; YERSINIA PESTIS;

ANIMALS; ANTIBODIES, BACTERIAL; BIOLOGICAL WARFARE; BIOMEDICAL RESEARCH; HUMANS; IMMUNITY, CELLULAR; PLAGUE; PLAGUE VACCINE; VACCINES, ATTENUATED; YERSINIA PESTIS;

EID: 40549101035     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.2.209     Document Type: Review

References (134)